Mysterious Autoimmune Sleep Sabotage Exposed

Your immune system can declare war on your sleep so completely that it erases the boundary between dreaming and waking — and the specific antibody doing the attacking determines whether you get your life back or not.

Story Snapshot

Autoimmune encephalopathies can produce dramatic sleep disorders — including severe insomnia, dream enactment, and sleep apnea — as primary or early symptoms.
Antibodies targeting cell-surface proteins like leucine-rich glioma-inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) produce recognizable sleep signatures and often respond well to immunotherapy.
Morvan syndrome, driven by CASPR2 antibodies, can cause a terrifying condition called agrypnia excitata — a state of near-total sleeplessness with hallucinations and extreme nervous system overactivity.
Antibodies targeting proteins inside neurons, such as anti-Ma2, tend to cause more permanent brain damage, are harder to treat, and carry a stronger link to underlying cancer.

When Your Immune System Attacks Your Sleep Architecture

Sleep disorders affect more than half of patients with autoimmune encephalitis, and they span nearly every category of sleep pathology — insomnia, hypersomnia, parasomnias, fragmented sleep, and sleep-disordered breathing. ^[9] This is not coincidental background noise. In many cases, the sleep disruption is the first and loudest signal that something immunologically catastrophic is underway inside the brain. The specific pattern of disruption offers a diagnostic fingerprint, if clinicians know what to look for.

Polysomnography — the gold-standard overnight sleep study — has proven its value in this population. A prospective series of patients with LGI1 and CASPR2 autoimmunity found objective evidence of dream enactment behavior, insomnia, REM sleep without atonia, sleep apnea, and shallower overall sleep architecture. ^[1] These are not soft subjective complaints. They show up on the recordings. Sleep disorders in autoimmune encephalitis appear in 20 to 65 percent of patients with LGI1 antibody encephalitis and 22 to 68 percent of those with CASPR2-associated disease. ^[7]

Morvan Syndrome: The Most Extreme Expression of Autoimmune Sleeplessness

Morvan syndrome sits at the severe end of the CASPR2 spectrum. It combines neuromyotonia — spontaneous, continuous muscle fiber activity — with dysautonomia, neuropsychiatric symptoms, and a sleep disorder so profound it has its own name: agrypnia excitata. ^[5] Patients experience near-total insomnia accompanied by hallucinations, motor agitation, and a nervous system that simply cannot downshift. ^[2] The condition is rare, but it illustrates how completely autoimmunity can dismantle normal sleep regulation when the right target is hit.

Insomnia is sometimes the presenting sign of Morvan syndrome — the symptom that brings the patient to medical attention before the fuller clinical picture emerges. ^[4] That makes it dangerously easy to misattribute to stress, anxiety, or primary insomnia. A 16-year-old boy presenting with back pain, insomnia, profuse sweating, and constipation following a respiratory illness was eventually found to carry both CASPR2 and LGI1 antibodies. ^[6] Without that index of suspicion, the autoimmune origin gets missed and the window for treatment narrows.

Why the Antibody Target Changes Everything About Prognosis

The distinction between cell-surface antibody disorders and intraneuronal antibody disorders is not academic — it determines how much of the patient’s brain function is recoverable. Antibodies targeting surface proteins like LGI1 and CASPR2 interfere with receptor function without necessarily destroying the neuron itself. Remove the antibody, restore the function. That is why immunotherapy tends to work well in these patients. ^[4] Continuous insomnia is actually more common in CASPR2 encephalitis than in LGI1 encephalitis, suggesting that even within the cell-surface category, specific targets produce distinct clinical signatures. ^[8]

Intraneuronal antibodies like anti-Ma2 operate differently. They target proteins inside the cell, the immune response causes structural neuronal damage, and that damage does not reverse when the antibody is cleared. Anti-Ma2 encephalitis frequently involves hypothalamic injury — which directly disrupts sleep-wake regulation — and it carries a strong paraneoplastic association, meaning a tumor is often driving the immune response. ^[10] Treating the sleep disorder in these patients requires finding and treating the cancer. The sleep problem is downstream of something far more serious.

The Honest Complexity That Gets Left Out of Simple Explanations

The surface-versus-intraneuronal framework is genuinely useful, but the real-world evidence resists clean categories. Sleep disturbances appear across the full spectrum of autoimmune encephalitides, including anti-N-methyl-D-aspartate receptor encephalitis, anti-IgLON5 disease, and others. ^[10] The specific sleep phenotype reflects not just the antibody class but where in the brain the immune attack concentrates — hypothalamus, brainstem, limbic structures — and how much collateral damage accumulates before treatment begins. ^[3] Antibody type is the best available shorthand for prognosis and treatment response, but it is a shorthand, not a guarantee. The patient who presents late, regardless of antibody class, faces a harder road. That is the part worth remembering when someone’s insomnia turns out to be the first symptom of something the immune system started long before anyone thought to look.